VYTRUS BIOTECH EO -01 Net Assets
VYTRUS BIOTECH EO -01 net assets. Based on the latest financial reports, VYTRUS BIOTECH EO -01 (V5P) has net assets worth €10.31 Million EUR (≈ $12.05 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€14.66 Million ≈ $17.14 Million USD) and total liabilities (€4.35 Million ≈ $5.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of VYTRUS BIOTECH EO -01 to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €10.31 Million |
| % of Total Assets | 70.3% |
| Annual Growth Rate | 24.79% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14.05 |
Net Assets of VYTRUS BIOTECH EO -01 (2021–2025)
Net assets of VYTRUS BIOTECH EO -01 from 2021 to 2025. This chart illustrates how VYTRUS BIOTECH EO -01's net assets have evolved over time, based on quarterly financial data. See how leveraged is VYTRUS BIOTECH EO -01's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for VYTRUS BIOTECH EO -01 (2021–2025)
The table below shows the annual net assets of VYTRUS BIOTECH EO -01 from 2021 to 2025. For live market cap and overall valuation, see V5P market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €10.31 Million ≈ $12.05 Million |
+41.34% |
| 2024-12-31 | €7.29 Million ≈ $8.53 Million |
+37.80% |
| 2023-12-31 | €5.29 Million ≈ $6.19 Million |
+11.34% |
| 2022-12-31 | €4.75 Million ≈ $5.56 Million |
+11.83% |
| 2021-12-31 | €4.25 Million ≈ $4.97 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to VYTRUS BIOTECH EO -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 543.7% over the analyzed period, indicating profitable operations and earnings retention.
VYTRUS BIOTECH EO -01 Net Assets Breakdown (December 2025)
VYTRUS BIOTECH EO -01 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.90 Million | 28.10% |
| Other Components | €7.41 Million | 71.90% |
| Total Equity | €10.31 Million | 100.00% |
VYTRUS BIOTECH EO -01 Competitors by Market Cap
The table below lists competitors of VYTRUS BIOTECH EO -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BARKBY GRP PLC LS 000860
F:3WY
|
$125.67 Million |
|
Grupo Clarin S.A.
BA:GCLA
|
$125.69 Million |
|
Heritage Distilling Holding Company, Inc. Common Stock
NASDAQ:CASK
|
$125.83 Million |
|
SKM Egg Products Export (India) Limited
NSE:SKMEGGPROD
|
$125.87 Million |
|
Lu Thai Textile
SHE:200726
|
$125.57 Million |
|
Kyochon F And B Co Ltd
KO:339770
|
$125.56 Million |
|
AOPEN Inc
TW:3046
|
$125.55 Million |
|
Aurum Resources Ltd
AU:AUE
|
$125.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VYTRUS BIOTECH EO -01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,292,825 to 10,308,016, a change of 3,015,191 (41.3%).
- Net income of 2,896,637 contributed positively to equity growth.
- Share repurchases of 867,375 reduced equity.
- New share issuances of 824,353 increased equity.
- Other factors increased equity by 161,576.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.90 Million | +28.1% |
| Share Repurchases | €867.37K | -8.41% |
| Share Issuances | €824.35K | +8.0% |
| Other Changes | €161.58K | +1.57% |
| Total Change | €- | 41.34% |
Book Value vs Market Value Analysis
This analysis compares VYTRUS BIOTECH EO -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23.25x to 10.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.62 | €14.30 | x |
| 2022-12-31 | €0.69 | €14.30 | x |
| 2023-12-31 | €0.79 | €14.30 | x |
| 2024-12-31 | €0.97 | €14.30 | x |
| 2025-12-31 | €1.37 | €14.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VYTRUS BIOTECH EO -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 28.10%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 34.60%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.42x
- Recent ROE (28.10%) is above the historical average (15.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 10.59% | 16.05% | 0.39x | 1.69x | €24.98K |
| 2022 | 12.73% | 16.44% | 0.46x | 1.68x | €129.92K |
| 2023 | 10.30% | 14.58% | 0.40x | 1.76x | €15.72K |
| 2024 | 14.00% | 20.24% | 0.45x | 1.53x | €291.72K |
| 2025 | 28.10% | 34.60% | 0.57x | 1.42x | €1.87 Million |
Industry Comparison
This section compares VYTRUS BIOTECH EO -01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VYTRUS BIOTECH EO -01 (V5P) | €10.31 Million | 10.59% | 0.42x | $125.66 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more